Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAS-120 in advanced solid tumors with FGFR alterations detected in circulating tumor DNA
jRCT2080224555Phase 2Completed
- Sponsor
- National Cancer Center Hospital East
- Start
- Feb 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of futibatinib in Non-hematologic malignancy, sponsored by National Cancer Center Hospital East. Primary endpoint: Primary efficacy and safety endpoints. Started Feb 2019; status: completed.
02
Drugs
futibatinib
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on jRCT2080224555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224555.